ARTICLE | Management Tracks
Janux picks Janeen Doyle to lead BD
Plus: Cohen-Dayag hands off CEO job, becomes Compugen’s executive chair, and a new CMO at Inozyme
May 16, 2025 1:14 AM UTC
As Janux Therapeutics Inc. (NASDAQ:JANX) moves two promising therapeutics through the clinic, the biotech has named Janeen Doyle chief corporate and business development officer. Doyle was most recently SVP of strategy and business development at Bristol Myers Squibb Co. (NYSE:BMY); she ended a 15-year run at that pharma and Celgene Inc. last year. Janux’s JANX007 is in Phase Ib testing for prostate cancer, and its EGFR-targeting JANX008 is in a Phase I trial to treat solid tumors.
After leading Compugen Ltd. (NASDAQ:CGEN; Tel Aviv:CGEN) as president and CEO since 2010, Anat Cohen-Dayag is handing the role to Eran Ophir, formerly CSO, as she becomes executive chair. Paul Sekhri is stepping down as chair...